Heparinoids (Heparinoid)

Heparin derivatives. The term has also been used more loosely to include naturally occurring and synthetic highly-sulphated polysaccharides of similar structure. Heparinoid preparations have been used for a wide range of applications including as anticoagulants and anti-inflammatories and they have been claimed to have hypolipidemic properties. (From Martindale, The Extra Pharmacopoeia, 30th, p232)

Also Known As:

Networked: 404 relevant articles (34 outcomes, 56 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Burroughs, A K: 4 articles (02/2009 - 02/2005)
2.	Ito, Ryoko: 3 articles (01/2021 - 05/2018)
3.	Kawamori, Jiro: 3 articles (01/2021 - 05/2018)
4.	Sekiguchi, Kenji: 3 articles (01/2021 - 05/2018)
5.	Zhang, Lijuan: 3 articles (01/2019 - 04/2016)
6.	Burroughs, Andrew K: 3 articles (06/2014 - 10/2002)
7.	Davenport, Andrew: 3 articles (07/2011 - 01/2001)
8.	Senzolo, M: 3 articles (02/2009 - 04/2007)
9.	Riddell, A: 3 articles (02/2008 - 02/2005)
10.	Counsell, C: 3 articles (04/2005 - 01/2000)

Related Diseases

1.	Ischemic Stroke 09/01/1993 - "Low molecular weight heparinoids (LMWHs) offer a new treatment option to patients experiencing acute ischemic stroke. " 07/01/2000 - "Low-molecular-weight heparins and heparinoids in acute ischemic stroke : a meta-analysis of randomized controlled trials." 11/01/1988 - "Recent advances in noninvasive diagnostic techniques to detect DVT early and the development of relatively safe heparinoid compounds increase the need for a prophylactic study in patients with ischemic stroke." 09/01/1993 - "Use of heparinoids to treat acute ischemic stroke." 12/01/1990 - "Low-molecular-weight heparins and heparinoids and their use in acute or progressing ischemic stroke."
2.	Venous Thrombosis (Deep-Vein Thrombosis) 01/23/1992 - "The incidence of deep-vein thrombosis was 56.6% and 15.5% respectively in the placebo and heparinoid treated patients (incidence reduction: 74%; P less than 0.001). " 01/23/1992 - "Prevention of deep vein thrombosis following total hip replacement by low molecular weight heparinoid." 01/01/2017 - "LMWH or heparinoid were associated with a significant reduction in deep vein thrombosis (DVT) compared with UFH (OR 0.55, 95% CI 0.44 to 0.70, 7 trials, 2585 participants, low quality evidence). " 04/18/2005 - "Allocation a to low-molecular-weight heparin or heparinoid was associated with a significant reduction in the odds of deep vein thrombosis (Peto odds ratio 0.52, 95% confidence interval 0.56 to 0.79). " 01/01/2001 - "When systemic anticoagulation is also required to treat venous thrombosis, then synthetic heparinoids or recombinant hirudin will be the agents of choice. "
3.	Thrombocytopenia (Thrombopenia) 04/01/1991 - "This is the first report of thrombocytopenia caused by heparinoid. " 03/02/1992 - "In no case was there an exacerbation of the thrombocytopenia nor thromboembolic complications while on heparinoid therapy. " 01/01/2020 - "Since excessive platelet activation and in situ thrombosis occur in HIT, this case underscores the need to consider that thrombocytopenia in patients with SARS-CoV-2-most of whom receive heparinoids-may be unrecognized HIT. " 03/01/1995 - "[Successful therapy of heparin-associated thrombocytopenia with a low sulfated heparinoid]." 01/01/1992 - "[Heparin-associated thrombocytopenia: successful therapy of patients after prospective selection of a compatible heparinoid with the heparin-induced platelet activation test]."
4.	Stroke (Strokes) 01/01/2001 - "PC patients did not show any particular benefit from anticoagulation, and the efficacy of heparinoid did not vary between AC and PC stroke. " 12/01/2001 - "However, an i.v. low-molecular-weight heparinoid showed a trend toward improving long-term outcome in subgroup of patients with atherothrombotic stroke. " 01/01/2001 - "For favorable outcome, there was no interaction between vascular distribution and treatment category, suggesting that the effect of heparinoid did not differ between PC and AC strokes. " 08/01/1999 - "The potential role of LMWHs and heparinoids in acute stroke remains to be clarified." 03/01/1965 - "[USE OF A SYNTHETIC HEPARINOID IN THE TREATMENT OF CEREBROVASCULAR ACCIDENTS IN AGED SUBJECTS]."
5.	Dermatitis 02/07/2019 - "We conducted a randomized trial to evaluate the efficacy of heparinoid moisturization for radiation dermatitis. " 05/01/2018 - "The prospective open-label, randomized trial included an exploratory arm to investigate the preventive efficacy of heparinoid moisturizer for acute radiation dermatitis (ARD). " 05/01/2018 - "Efficacy of heparinoid moisturizer as a prophylactic agent for radiation dermatitis following radiotherapy after breast-conserving surgery: a randomized controlled trial." 04/01/2012 - "Topical application of Sema3A, betamethasone and tacrolimus ointments significantly inhibited scratching behavior and improved dermatitis scores in Dfb-treated mice compared with control mice, whereas vaseline and heparinoid had no effects. "

Related Drugs and Biologics

1.	Heparin (Liquaemin)
2.	danaparoid (Orgaran)
3.	Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)
4.	Aspirin (Acetylsalicylic Acid)
5.	Ointments (Pastes)
6.	Factor Xa (Coagulation Factor Xa)
7.	Hirudoid
8.	Blood Glucose (Blood Sugar)
9.	Antithrombins
10.	Fondaparinux (Arixtra)

Related Therapies and Procedures

1.	Therapeutics
2.	Catheters
3.	Intravenous Infusions
4.	Hip Replacement Arthroplasty (Total Hip Replacement)
5.	Rhinoplasty